Loading Page..

Knowledge Content Library

507
Eli Lilly PoS Estimation and Reference Class Forecasting – What BioPharma can Learn from Probabilistic Forecasts in Energy
By Jay Andersen, Charles Persinger, Reidar Bratvold, Probability of Success User Interest Group Meeting

477
Simulation of the Portfolio of COVID-19 Vaccines
By Vladimir Shnaydman and Jack Scannell, Pharma Interest Group Meeting

473
Impact of Covid-19 Test Reliability
By Brian Putt, San Francisco Chapter Meeting

443
Case Study: Self-Serve, Multi-Use Decision Frameworks: A Case Study Exemplifying the Top 5 Techniques
Case Study by Tyler Ludlow, Decision Skills Institute at 2019 DAAG Conference in Denver. This presentation will demonstrate the top 5 techniques for developing self-serve, multi-use decision frameworks by presenting the case of a pharmaceutical company looking to improve their quality assessment process of third-party contractors.

452
Life Sciences Track: Data and Decision Making in Drug Development
Panel discussion with David Wolter, IQVIA; Kirk Solo, Lexidyne Consulting; Thomas Abbott, Real World Informatics; Ian Bonzani, IQVIA at 2019 DAAG Conference in Denver. In this Life Sciences Mini-Conference, this talk covers what data are companies using and what new insights do they find most valuable?

429
Life Sciences Track: Why Do We Need DA When We Have AI?
Panel discussion with Joanna Wolkowski, Pfizer; Julie Schiffman, Pfizer; Leslie Lippard, Genetech; Pratap Khedkar, ZS Associates at 2019 DAAG Conference in Denver. In this Life Sciences Mini-Conference, this talk covers how would DA be used in the future? Will AI eventually replace decision professionals and decision-makers?

430
Life Sciences Track: How Sure Are You?: Epistemology of Clinical Research and DA
Fireside Chat with Steven Goodman, Stanford at 2019 DAAG Conference in Denver. In this Life Sciences Mini-Conference, this talk covers the reliance on classical statistics without bayesian considerations in epistemology studies in medical research.

374
I learned about DA from That!
Presented by Rodger Thompson (Pfizer) at 2017 DAAG Conference in New Orleans. In this session on Coaching and Knowledge Transfer, this talk covers lessons learned from over 20 years of DA practice, including communicating to management.

373
A "Cap & Trade" Approach to Assessing Technical Success Probabilities in Pharma
Presented by Chris Dalton (Syncopation Software) at 2017 DAAG Conference in New Orleans. In this session on Learning and Organization, this talk discusses probability assessment in the context of pharma/biotech R&D portfolio management.

371
The Value and Danger of “Story” in Getting to Commitment to Action
Presented by Elayne Ko (Pfizer) and Charles Persinger (Eli Lilly) at 2017 DAAG Conference in New Orleans. In this session on Facilitation and Collaboration, this talk discusses both the value and danger of using stories to facilitate commitment to action.

355
Modeling Ordered Uncertainties
Presented by Jon Mauer (Pfizer) at 2016 DAAG Conference in Banff. In this session on The Cutting Edge of Decision Analysis, this short talk looks at complex correlated uncertainties in a pharma problem.

325
Improved Drug Treatment Decisions Through Consistent Benefit‐Risk Tradeoffs
Presented by Jack Kloeber (Kromite) at 2016 DAAG Conference in Banff. In this session on Medical Decision Making, this talk discusses the use of multi-objective decision analysis to aid physicians in finding effective ways to measure and communicate the differences in treatment benefits and risks.

323
The Journey to Organizational Decision Quality
Presented by Raiffa-Howard Award recipients (Pfizer, Lilly, Chevron) at 2016 DAAG Conference in Banff. In this session on Corporate and Organizational Decision Quality (ODQ), this panel discussion is focused on the journey to ODQ with new award recipients sharing their perspective, learnings, and advice.

308
Improving decision quality: one decision at a time
Presented by Karen Sepucha (Health Decision Sciences Center - Massachusetts General Hospital) at 2015 DAAG Conference in Huntington Beach. This keynote speech discusses the use of decision sciences to improve medical decision making at Mass General.

295
All is Never Really Said and Done: Actively Navigating Benefit and Risk
Presented by Marilyn Metcalf (GlaxoSmithKline) at 2013 DAAG Conference in Austin. Discussion of assessing and managing benefit versus risk.

293
Is This Thing Safe? Decision Analysis in Consumer Product Safety
Presented by Jeremy Jokinen (Johnson & Johnson) at 2013 DAAG Conference in Austin. Discussion of methods including surveillance for ensuring that released products are safe.

284
Project Portfolio Management Best Practices Summary of Results
Presented by Michael Menke (Value Creation Associates) at 2012 DAAG Conference in Chicago. A benchmarking study captures the practices and pitfalls in PM. Generic recommendations are available and should be considered by those practitioners wishing to make improvements and impacts.

285
Processes and Tools of Portfolio Management: A Baxter Case Study
Presented by Phil Beccue (Baxter) at 2012 DAAG Conference in Chicago. Case study touches upon evolution of portfolio methods, where the organization is today, where it is headed with regards to PM. Includes challenges addressed along with perspectives from others in Baxter.

286
Should you create project level alternatives in portfolios?
Presented by Jeffrey Kiesler (University of Massachusetts) at 2012 DAAG Conference in Chicago. One way that portfolio decision analysis adds value is by improving the set of alternatives from which we choose. This set can be enriched by generating multiple alternatives involving different amounts of funding at the project level.

287
The use of decision analysis for Phase 2 and Phase 3 drug development decisions
Presented by Elayne Ko (Deloitte) and Charles Persinger (Eli Lilly) at 2012 DAAG Conference in Chicago. The characteristics of drug development in Phase 2 and 3 are explored, and the implications of applying decision analysis process for the Phase 2 and 3 drug development decisions are highlighted.

Stay connected